Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Vestal Point Capital LP

Vestal Point Capital LP grew its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 22.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 645,000 shares of the company's stock after purchasing an additional 120,000 shares during the period. Vestal Point Capital LP owned approximately 0.76% of Verve Therapeutics worth $3,638,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its position in shares of Verve Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company's stock valued at $101,000 after acquiring an additional 1,676 shares during the period. Rhumbline Advisers increased its position in shares of Verve Therapeutics by 1.9% in the 4th quarter. Rhumbline Advisers now owns 111,203 shares of the company's stock valued at $627,000 after acquiring an additional 2,093 shares during the period. Arizona State Retirement System increased its position in shares of Verve Therapeutics by 15.8% in the 4th quarter. Arizona State Retirement System now owns 19,593 shares of the company's stock valued at $111,000 after acquiring an additional 2,669 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Verve Therapeutics by 5.8% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 50,230 shares of the company's stock valued at $313,000 after acquiring an additional 2,742 shares during the period. Finally, Invesco Ltd. increased its position in shares of Verve Therapeutics by 5.7% in the 4th quarter. Invesco Ltd. now owns 57,140 shares of the company's stock valued at $322,000 after acquiring an additional 3,080 shares during the period. Hedge funds and other institutional investors own 97.11% of the company's stock.

Verve Therapeutics Trading Down 0.5%

Shares of VERV stock traded down $0.02 on Friday, reaching $4.36. 1,383,381 shares of the stock were exchanged, compared to its average volume of 1,859,907. The business's 50 day moving average price is $4.61 and its 200 day moving average price is $5.81. The company has a market capitalization of $388.66 million, a price-to-earnings ratio of -1.77 and a beta of 1.82. Verve Therapeutics, Inc. has a twelve month low of $2.86 and a twelve month high of $9.31.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The business had revenue of $32.98 million during the quarter, compared to analysts' expectations of $7.13 million. Equities research analysts forecast that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on VERV. Canaccord Genuity Group increased their target price on shares of Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a research note on Tuesday, April 15th. Royal Bank of Canada lowered their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 4th. Guggenheim increased their target price on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, April 15th. Cantor Fitzgerald raised shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Tuesday, April 15th. Finally, William Blair reaffirmed an "outperform" rating on shares of Verve Therapeutics in a research note on Friday, February 21st. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $25.75.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.